Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Rhea-AI Summary
Guardant Health, Inc. (GH) will participate in investor conferences, including Citi 2024 Unplugged Medtech and Life Sciences Access Day and TD Cowen 44th Annual Health Care Conference. Interested parties can access live and archived webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
-
News
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will report financial results for Q4 and full year 2023 on February 22, 2024. The company will webcast the conference call, with live audio available on their website. Investors can access the archived webcast for replay after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium. The test is highly specific and predictive for recurrence, without dependence on a tissue sample.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
Rhea-AI Summary
Guardant Health, a leading precision oncology company, announced a 25% revenue growth driven by a 39% increase in clinical volume. The company reported revenue of $562-563 million for the full year 2023, with a 21% increase in revenue for the fourth quarter. However, the preliminary unaudited free cash flow was approximately negative $84 million for the fourth quarter and approximately negative $347 million for the full year 2023. Cash, cash equivalents, and marketable debt securities were $1.2 billion as of December 31, 2023. Guardant Health plans to report its fourth quarter and full year audited financial results for the period ended December 31, 2023, during its February 2024 earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) and Hikma Pharmaceuticals PLC announced a partnership to promote Guardant Health’s cancer screening and monitoring tests in the Middle East and North Africa. The agreement aims to improve access to next-generation sequencing tests in the region, where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
-
Rhea-AI Summary
Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) appoints Terilyn Juarez Monroe as Chief People Officer to lead human resources, talent acquisition, and diversity and inclusion initiatives. Monroe brings extensive experience from previous roles at Bonterra, Varian, Acxiom, and Intuit, with a focus on scaling and developing world-class teams and cultures. She aims to support Guardant's mission to revolutionize cancer screening and detection, providing patients with more quality time with their families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) has entered into a common stock purchase agreement with Baillie Gifford for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share, resulting in gross proceeds of approximately $90.7 million. The net proceeds will be used primarily for general corporate purposes, including working capital, operating expenses, and capital expenditures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will present and participate in a Q&A session on Monday, January 8, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties can access live and archived webcasts of the sessions on the 'Investors' section of the company website at www.guardanthealth.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) announced that the U.S. FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for its Shield™ blood test to screen for colorectal cancer on March 28, 2024. The submission includes data from the company’s positive ECLIPSE study, an over 20,000-patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.61%
Tags
FAQ
What is the current stock price of Guardant Health (GH)?
The current stock price of Guardant Health (GH) is $32.65 as of November 22, 2024.
What is the market cap of Guardant Health (GH)?
The market cap of Guardant Health (GH) is approximately 4.0B.
What does Guardant Health, Inc. specialize in?
Guardant Health specializes in liquid-based cancer tests, providing non-invasive diagnostic tools for clinical and research use.
What are the main products offered by Guardant Health?
Guardant Health offers Guardant360 LDT, Guardant360 CDx, Guardant OMNI, Reveal, and Shield, which are various liquid biopsy tests for cancer detection and treatment selection.
What is Guardant360 CDx?
Guardant360 CDx is an FDA-approved companion diagnostic test used to guide targeted cancer therapies.
How does Guardant Health support cancer research?
Guardant Health aids cancer research through products like Guardant OMNI and services such as regulatory approval consultancy and clinical trial referrals.
What is the significance of the Reveal test?
Reveal is a tumor-agnostic molecular residual disease (MRD) test that helps monitor cancer recurrence or residual disease at the molecular level.
What is the purpose of the Shield test?
The Shield test is a non-invasive liquid biopsy for colorectal cancer (CRC) screening.
Who are some of the major investors in Guardant Health?
Guardant Health has received investments from Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank.
Where is Guardant Health, Inc. headquartered?
Guardant Health, Inc. is headquartered in Redwood City, California.
What is the Guardant360 LDT test used for?
Guardant360 LDT is used for treatment selection in patients with advanced-stage cancer.
How does Guardant Health contribute to early cancer detection?
Guardant Health contributes to early cancer detection through its pioneering products and ongoing research in liquid biopsy technologies.
Guardant Health, Inc.
Nasdaq:GH
GH Rankings
GH Stock Data
4.02B
117.89M
4.56%
104.62%
8.33%
Diagnostics & Research
Services-medical Laboratories
United States of America
PALO ALTO